AEs such as fever, rash, myalgia, and arthralgia, thought to be allergic reactions, have been observed in patients able to tolerate AZA at therapeutic doses, leading researchers to question the nature of these events, suggesting that they are related to a type of hypersensitivity reaction, rather than TPMT pharmacogenetics [7]. This evidence concerns the gene TPMT and hypersensitivity reaction disease.